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background: Although dofetilide is widely used in the United States for rhythm control in patients with symptomatic atrial fibrillation (AF), there is 
minimal safety data in the AF population despite its known risk of Torsade de pointes (TdP).
methods: We conducted a retrospective chart review of a cohort of 1,404 patients who were loaded on dofetilide for atrial arrhythmia suppression 
at the Cleveland Clinic from 2008-2012 to evaluate the risk of in-hospital adverse events.
results: Of the 17 patients who had TdP during inpatient loading (1.2%), 10 had a cardiac arrest requiring resuscitation (of whom 1 died), 5 had 
syncope/pre-syncope with no required resuscitation and 2 were asymptomatic. There were 3 in-hospital deaths (0.2%): 1) TdP in a patient with 
critical aortic stenosis; 2) pulseless electrical activity secondary to cardiac amyloidosis (no longer on drug at the time); and 3) acute bowel ischemia 
causing lactic acidosis. The other 2 major inpatient adverse events were a transient ischemic attack and an asystolic arrest. Dofetilide loading was 
stopped for 106 patients (7.5% of the cohort) due to QTc prolongation or TdP. Patients with TdP were more likely to have heart failure, a significantly 
lower ejection fraction and a greater increase in QTc from baseline.
conclusions: Dofetilide loading has a low but finite risk of TdP and other adverse events.
Table 1. Characteristics of patients in relation to occurrence of TdP
Variable TdP (n = 17) No TdP (n=1,387) p value
Female gender 9 (53%) 472 (34%) 0.10
Age, mean ± s.d. 68.5 ± 11.8 66.5 ± 10.6 0.19
GFR (MDRD), (mL/min), median (IQR) 66 (54, 76) 74 (61, 87) 0.10
Diabetes 6 (35%) 418 (30%) 0.65
Hypertension 16 (94%) 1363 (98%) 0.26
Coronary artery disease 11 (65%) 635 (46%) 0.12
Paroxysmal 3 (18%) 442 (32%) 0.21
Ejection Fraction (%), median (IQR) 35 (20, 45) 52 (40, 55) 0.001
Congestive Heart Failure Hx 13 (76%) 575 (41%) 0.004
Electrical Cardioversion 7 (41%) 530 (38%) 0.80
QRS duration (ms), median (IQR) 94 (88, 128) 98 (88, 116) 0.90
Pre-load QTc (ms), median (IQR) 384 (364, 440) 396 (360, 432) 0.85
Delta QTc (ms), median (IQR) 54 (-3.7, 125) 17 (-6.7, 39) 0.01
Delta QTc (%), median (IQR) 12 (-1, 27) 4 (-1, 9) 0.02
